Table 1. Experimental conditions utilized in the microarray studies.
| Treatment Name (N) | Treatment Description |
| T0 (3) | No treatment, time 0 control |
| PBS 6 hr (4) | PBS-exposed, harvested at 6 hr |
| PBS 24 hr (4) | PBS-exposed, harvested at 24 hr |
| AZT 6 hr (3) | AZT-treated, harvested at 6 hr |
| AZT 24 hr (4) | AZT-treated, harvested at 24 hr |
| AZT 48 hr (3) | AZT-treated, harvested at 48 hr |
| SMM 6 hr (4) | SMM-exposed, harvested at 6 hr |
| SMM 24 hr (3) | SMM-exposed, harvested at 24 hr |
| AZT 48 hr+SMM 6 hr (3) | AZT-treated for 48 hr; SMM-exposed during last 6 hrs |
| AZT 72 hr+SMM 24 hr (3) | AZT-treated for 72 hr; SMM-exposed during last 24 hrs |
PBS: 30 µl mucosal phosphate-buffered saline; AZT: 30 µg/ml serosal azithromycin. SMM: 30 µl mucosal supernatant from mucopurulent material from CF airways. N = number of arrays from 4 different human HBE codes that were used for subsequent analyzes.